

Lan Xu

Personal Information:

Sex:	Female	Address:	Pater Damiaanstraat 25,
Date of Birth:	January 28th, 1987		Wilrijk, 2610, Belgium
Nationality:	China	Telephone:	+32 (0) 486 478 613
Marital Status:	Married	Email:	xulan1987@gmail.com

Achievements:

- Recipient of the grant of “the 2018 Chinese Government Award for Outstanding Self-financed Students Abroad” by China Scholarship Council.

Work Experience:

11/2013-present **Epidemiologist**, Belgian Cancer Centre/Unit of Cancer Epidemiology, Sciensano (former name: Scientific Institute of Public Health, WIV-ISP), Brussels, Belgium.

Education:

09/2015-present **Ph.D. student in Faculty of Medicine and Health Sciences, Ghent University, Belgium**

- Thesis title: “Systematic reviews and meta-analyses of primary and secondary prevention for HPV-related Anogenital diseases”

09/2011–10/2013 **Master of Science in Statistics in Katholieke Universiteit Leuven, Leuven, Belgium**

- Course Modules: Statistics for Finance and Insurance, Sampling Theory, Survey Methodology, Linear Regression and Analysis of Variance, Generalized linear Models, Multivariate Analysis, Statistical Modeling, Advanced Econometrics, Advanced Time Series Analysis, Multilevel Analysis Experimental Design.

Scientific Publications:

1. **Xu L**, Benoy I, Cuschieri K, Poljak M, Bonde J and Arbyn M. Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. Expert Review of Molecular Diagnostics 2019; 19(6): 543-51.
2. **Xu L**, Padalko E, Ostrebenk A, Poljak M, Arbyn M. Clinical evaluation of INNO-LiPA HPV Genotyping EXTRA II assay using the VALGENT framework. International Journal of Molecular Sciences 2018;19(9).pii:E2704.
3. Arbyn M*, **Xu L***, Simons C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD009069.

*Joint first authors

4. Arbyn M and **Xu L**, Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomised trials. *Expert Review of Vaccines*. 17 (12):1085-1091, 2018.
5. **Xu L**, Ostrebenk A, Poljak M, Arbyn M. Assessment of the Roche Linear Array HPV Genotyping test within the VALGENT framework. *Journal of Clinical Virology* 2018; 98:37-42.
6. **Xu L**, Verdoodt F, Wentzensen N, Bergeron C, Arbyn M. Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. *Cancer Cytopathology* 2016;124: 261-72.
7. Polman NJ, Ostrebenk A, **Xu L**, et al. Evaluation of the clinical performance of the HPV-Risk assay using the VALGENT-3 panel. *J Clin Microbiol* 2017; 55:3544–3551.
8. Arbyn M, **Xu L**, Verdoodt F, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. *Ann Intern Med* 2017;166: 118-27.
9. Arbyn M, **Xu L**, Wentzensen N. HPV test results provide useful risk stratification information in women with ASC-H Pap test findings. *Cancer Cytopathol* 2016;124: 754-5.

Conference contributions:

1. **Xu L** and Ejegod D. HPV assays on SurePath media in VALGENT4. EUROGIN2018, Lisbon, Portugal (Invited speaker of the congress).
2. **Xu L** et al. Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. EUROGIN 2018, Lisbon, Portugal (Oral presentation).
3. **Xu L** and Arbyn M. Clinical validation of the Liferiver Harmonia HPV assay using the VALGENT-4 framework. HPV 2018, 32nd International Papillomavirus Conference, Sydney, Australia (Oral presentation).
4. **Xu L**, Arbyn M et al. Optimization of the RIATOL qPCR HPV genotyping assay by choosing a threshold assuring satisfactory accuracy to detect high grade cervical intraepithelial neoplasia. EUROGIN2017, Amsterdam, Netherlands (Oral presentation).
5. **Xu L**, Arbyn M et al. A new title for Cochrane review: the efficacy of prophylactic HPV vaccination against vulvar and vaginal cancer and its precursors. HPV2017, 31st International Papillomavirus Conference, Cape Town, South Africa (Oral presentation).
6. **Xu L**, Arbyn M et al. Assessment of the Roche Linear Array HPV genotyping test within the VALGENT framework, HPV2017, 31st International Papillomavirus Conference, Cape Town, South Africa (Poster presentation).
7. **Xu L**, Arbyn M. Triage of ASC-H: a systematic review and meta-analysis of the accuracy of hrHPV testing and other markers to detect cervical precancer EUROGIN 2016 Conference: Key findings in HPV associated cancers. EUROGIN. Salzburg: 2016. Austria (Oral presentation).